Inovio to net $23 million from private offering, partly to fund trial with cervical cancer DNA vaccine
This article was originally published in Scrip
Executive Summary
Inovio Pharmaceuticals, a publicly-quoted firm based in Blue Bell, PA, expects to raise $23 million from a single, undisclosed institutional investor part of which will fund its planned Phase II clinical study with its DNA vaccine against cervical dysplasia and cancers.